|Day's Range||0.0600 - 0.0600|
Johnson & Johnson said it will discontinue the late-stage study of its experimental respiratory syncytial virus (RSV) adult vaccine, weeks after rivals Pfizer and GSK gained a lead in the race for the first vaccine against the virus. J&J made the decision in order to "to focus on medicines with the greatest potential benefit to patients," the company said on Wednesday. J&J started the study following positive results from a mid-stage trial, which showed the vaccine was 80% effective in protecting against lower respiratory tract disease caused by RSV.
AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) are two of the world's biggest pharmaceutical companies, and the similarities don't end there. The case for AbbVie as a growth stock can't avoid two issues: the decline of Humira, and the stagnation of its oncology portfolio.
CIBC today announced the addition of six new Canadian Depositary Receipts ("CDRs"), now listed on the NEO Exchange.